PL3862010T3 - USING AKKERMANSIA MUCINIPHILA TO PROMOTE WEIGHT LOSS - Google Patents

USING AKKERMANSIA MUCINIPHILA TO PROMOTE WEIGHT LOSS

Info

Publication number
PL3862010T3
PL3862010T3 PL21154064.6T PL21154064T PL3862010T3 PL 3862010 T3 PL3862010 T3 PL 3862010T3 PL 21154064 T PL21154064 T PL 21154064T PL 3862010 T3 PL3862010 T3 PL 3862010T3
Authority
PL
Poland
Prior art keywords
weight loss
akkermansia muciniphila
promote weight
promote
muciniphila
Prior art date
Application number
PL21154064.6T
Other languages
Polish (pl)
Inventor
Patrice Cani
Amandine EVERARD
Clara BELZER
Willem De Vos
Original Assignee
Université Catholique de Louvain
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3862010(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Catholique de Louvain, Wageningen Universiteit filed Critical Université Catholique de Louvain
Publication of PL3862010T3 publication Critical patent/PL3862010T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
PL21154064.6T 2012-11-19 2013-11-15 USING AKKERMANSIA MUCINIPHILA TO PROMOTE WEIGHT LOSS PL3862010T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/073011 WO2014075745A1 (en) 2012-11-19 2012-11-19 Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
PL3862010T3 true PL3862010T3 (en) 2025-08-25

Family

ID=47257788

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21189951.3T PL3967315T3 (en) 2012-11-19 2013-11-15 Akkermansia muciniphila for treating cancer
PL21154064.6T PL3862010T3 (en) 2012-11-19 2013-11-15 USING AKKERMANSIA MUCINIPHILA TO PROMOTE WEIGHT LOSS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21189951.3T PL3967315T3 (en) 2012-11-19 2013-11-15 Akkermansia muciniphila for treating cancer

Country Status (14)

Country Link
US (10) US20150306152A1 (en)
JP (2) JP6426616B2 (en)
KR (7) KR20240137696A (en)
CN (2) CN104918626B (en)
AU (1) AU2013346726B2 (en)
BR (1) BR112015011403A2 (en)
CA (1) CA2891758C (en)
DK (1) DK2919796T3 (en)
EA (2) EA037315B1 (en)
ES (3) ES3038019T3 (en)
MX (1) MX365835B (en)
PL (2) PL3967315T3 (en)
PT (1) PT2919796T (en)
WO (2) WO2014075745A1 (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
KR101740893B1 (en) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 COMPOSITION COMPRISING EXTRACELLULAR VESICLES DERIVED FROM Akkermansia muciniphila AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING METABOLIC DISEASE
CA2964480A1 (en) * 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
PL3065748T3 (en) 2014-12-23 2018-07-31 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
KR20170091157A (en) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 Pirin polypeptide and immune modulation
HK1252412A1 (en) 2015-05-06 2019-05-24 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
PT3292135T (en) 2015-05-06 2022-11-15 Univ Catholique Louvain Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
SI3240554T1 (en) 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis and wexlerae for use in the treatment of inflammatory and autoimmune diseases
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3650033T2 (en) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compositions comprising bacterial strains
EA201890050A1 (en) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед COMPOSITIONS CONTAINING BACTERIAL STRAINS
CN105106245A (en) * 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Application of Akkermansia muciniphila BAA-835 strain
CN105030841A (en) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Application of Akkermansia muciniphila BAA-835 strain
BR112018004532B1 (en) * 2015-09-10 2022-03-15 Université Catholique de Louvain Use of pasteurized akkermansia for the treatment of metabolic disorders
JP2018534277A (en) 2015-10-05 2018-11-22 シュヴァイツェリッシェ フォルシュングスインスティテュート フュア ホーフゲブリクスクリーマ ウント メディツィン イン ダヴォス Use of Akkermansia muciniphila for treating inflammatory conditions
WO2017060491A1 (en) * 2015-10-09 2017-04-13 Biogaia Ab Mucus thickness to prevent diseases
CN105176822B (en) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 A kind of optimization separation method of human intestine probiotics
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
FI3639834T3 (en) 2016-02-04 2023-09-27 Univ Gent USE OF MICROBIAL COMMUNITIES FOR HUMAN AND ANIMAL HEALTH
EP4249053A3 (en) 2016-03-04 2024-06-19 The Regents of The University of California Microbial consortium and uses thereof
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX386592B (en) * 2016-04-11 2025-03-19 Univ Wageningen NEW BACTERIAL SPECIES.
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018012834A1 (en) 2016-07-11 2018-01-18 한국생명공학연구원 Akkermansia muciniphila strain having effect of preventing or treating degenerative brain diseases or metabolic diseases, and use thereof
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Composition comprising a bacterial strain
CN109874329B (en) * 2016-08-12 2023-08-29 深圳华大生命科学研究院 A kind of Faecalibacterium butyricum and its culture method and application
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018119048A1 (en) * 2016-12-20 2018-06-28 The Regents Of The University Of California Compositions and methods for inhibiting seizures
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
FR3065643B1 (en) 2017-04-26 2020-04-17 Usines Chimiques D'ivry La Bataille (Ucib) NUTRACEUTICAL AND / OR PHARMACEUTICAL COMPOSITION FOR STIMULATING THE PRODUCTION OF TYPE 2 BETA-DEFENSINS
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
JP7212945B2 (en) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド Compositions containing bacterial strains
TW201907931A (en) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 Composition comprising a bacterial strain
MD3804737T2 (en) 2017-06-14 2022-10-31 4D Pharma Res Limited Compositions comprising bacterial strains
CN115813955A (en) 2017-06-14 2023-03-21 4D制药研究有限公司 Compositions comprising bacterial strains
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
TWI640314B (en) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 Use of parabacteroides goldsteinii for reducing insulin resistance and improving glucose tolerance
TWI636788B (en) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 Use of parabacteroides goldsteinii to treat fatty liver disease
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. Methods and compositions for treatment of microbiome-associated disorders
WO2019092896A1 (en) * 2017-11-08 2019-05-16 アサヒグループホールディングス株式会社 Akkermansia muciniphila proliferation material
CN111683665A (en) * 2017-11-30 2020-09-18 格礼卡姆股份公司 Human milk oligosaccharides for microbiota modulation and their synthetic compositions
RU2020131222A (en) * 2018-03-02 2022-04-06 Академис Медис Сентрум FAECAL MATERIAL FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (en) * 2018-04-19 2021-03-10 주식회사 고바이오랩 Composition for preventing or treating immunometabolic diseases comprising Bacteroides vulgates
WO2019222359A1 (en) * 2018-05-15 2019-11-21 Duke University Systems and methods for genetic manipulation of akkermansia species
CN110496140B (en) * 2018-05-18 2022-05-31 瑞微（深圳）生物科技有限公司 Application of bacteroides fragilis or Ackmann myxobacterium in preparation of drugs for preventing or treating tumors
WO2019226723A1 (en) * 2018-05-23 2019-11-28 The Regents Of The University Of California Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
JP7811843B2 (en) 2018-07-19 2026-02-06 ペンデュラム セラピューティクス， インコーポレイテッド Methods and compositions for microbial engraftment
US20210177904A1 (en) * 2018-08-20 2021-06-17 Murdoch Children's Research Institute Behavioural treatment
CN110964650B (en) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 Bacterial strain for preventing and treating metabolic diseases and application thereof
WO2020071660A1 (en) * 2018-10-01 2020-04-09 한국생명공학연구원 Anti-aging composition containing akkermansia muciniphila strain or culture thereof as active ingredient
KR102197180B1 (en) 2018-10-11 2020-12-31 주식회사 고바이오랩 Akkermansia muciniphila and composition for controlling appetite or preventing, improving, relieving and treating metabolic disease comprising the same
WO2020076136A2 (en) * 2018-10-11 2020-04-16 서울대학교산학협력단 Akkermansia muciniphila strain and use thereof
EP3669944B1 (en) 2018-12-21 2023-12-20 Salomon Amar Use of akkermansia in the treatment of oral diseases
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
JP7402629B2 (en) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 Composition containing propionic acid bacteria fermented product
TWI719549B (en) * 2019-07-22 2021-02-21 大江生醫股份有限公司 Prebiotic composition for promoting growth of akkermansia muciniphila
KR102128287B1 (en) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK19 strain AND uses thereof
KR102128289B1 (en) 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK27 strain AND uses thereof
KR102520571B1 (en) * 2019-09-25 2023-04-13 (주)헬스바이옴 Strict anaerobic human gut microbe for antitumor treatment and uses thereof
KR102397916B1 (en) * 2019-10-01 2022-05-17 (주)헬스바이옴 A novel anaerobic microbe isolated from human milk and method of preventing or treating metabolic disease using thereof
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
CN110698547B (en) * 2019-10-31 2023-01-03 南京农业大学 Recombinant expression Ackermanella membrane protein Amuc _1100 and application thereof
CN110786376A (en) * 2019-11-07 2020-02-14 中南大学湘雅医院 Application of inactivated Ekmanella mucinophilus in preparing yogurt and preparation method and application of yogurt
CN111202752A (en) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 Akkermansia composition
CN111228315A (en) 2020-02-27 2020-06-05 上海上药信谊药厂有限公司 antitumor composition
CN111450233B (en) * 2020-03-19 2021-04-13 中国农业大学 Application of microbial metabolite in relieving glycolipid metabolic disorder
WO2021194281A1 (en) * 2020-03-25 2021-09-30 한국생명공학연구원 Tars derived from akkermansia muciniphila or fragment thereof, and use thereof
EP4560007A3 (en) * 2020-04-03 2025-08-13 International N&H Denmark ApS Compositions for metabolic health
WO2021215828A1 (en) * 2020-04-24 2021-10-28 주식회사 고바이오랩 Protein variant having glp-1 inducing activity and use thereof
CN111996267A (en) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 Fluorescent quantitative PCR (polymerase chain reaction) primer group and kit for rapidly detecting AKK (alkyl ketene dimer) bacteria and application of fluorescent quantitative PCR primer group and kit
KR102185827B1 (en) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 Pharmaceutical composition for preventing or treating atopic disease comprising akkermansia muciniphila strain
BE1028339B1 (en) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprising Akkermansia muciniphila and green tea extract
CN113116936A (en) * 2021-04-02 2021-07-16 上海市第六人民医院 Application of akkermansia muciniphila in preparation of beta-chenodeoxycholic acid inhibitor
CN113322202B (en) * 2021-05-31 2022-03-01 君维安(武汉)生命科技有限公司 Ackermanella, culture method and application thereof
KR102380194B1 (en) * 2021-06-11 2022-03-29 쿼럼바이오 주식회사 Composition for improving intestinal microbial population containing galactose
JP7398714B2 (en) * 2021-06-28 2023-12-15 東栄新薬株式会社 Akkermansia muciniphila proliferation-promoting composition applicable to medical and beauty treatments, as well as pharmaceuticals, food and beverages, and feed containing the same
CN113862193B (en) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 Acremonium muciniphilum and application thereof in preparation of antitumor drugs
AU2022386238A1 (en) * 2021-11-12 2024-06-27 Gelesis S.r.l. Compositions and methods for modulating the intestinal microbiome
CN119183472A (en) * 2022-03-15 2024-12-24 潘德勒姆治疗公司 Novel microbial compositions and methods of use thereof
CN114634892B (en) * 2022-03-24 2024-07-26 浙江省农业科学院 Probiotic composition with blood lipid reducing effect, preparation method and equipment
CN115804793B (en) * 2022-06-08 2025-08-15 石家庄普维生物科技有限公司 Application of akkermansia muciniphila in preparation of composition for improving alcoholic liver function abnormality, composition and application
CN116115647B (en) * 2022-06-08 2024-12-20 广州知易生物科技有限公司 Application of Akkermansia muciniphila in preparing pharmaceutical composition or health product composition for improving metabolic syndrome
CN114949002B (en) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 Application of akkermansia muciniphila in preparation of composition for preventing and treating atherosclerosis
CN115252651B (en) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 Application of akkermansia muciniphila in preparation of composition for preventing and treating hypertension and composition containing same
CN114949003B (en) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 Acremonium muciniphilum, application and culture method thereof
CN115463159A (en) * 2022-09-26 2022-12-13 暨南大学附属第一医院（广州华侨医院） Application of Acermanium and Acermanium postbiotic in preparation of medicine or health-care product for preventing or treating hepatic steatosis
CN115747357A (en) * 2022-11-15 2023-03-07 迪辅乐生物(上海)有限公司 Detection kit and detection method for intestinal mucinous-Ackermanella
WO2024134035A1 (en) * 2022-12-22 2024-06-27 Sorbonne Universite Composition and use of turicimonas muris for the treatment of metabolic diseases
CN116077536B (en) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof
CN116999468B (en) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Use of Akkermansia muciniphila in preparing products for preventing, treating and/or assisting in treating cardiovascular diseases
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
CN120265750A (en) * 2023-10-12 2025-07-04 雷文虎克生物技术股份有限公司 Ekmansia muciniphila and its use in preventing non-alcoholic fatty hepatitis
CN117603884B (en) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 Acremonium muciniphilum bacterial powder and preparation method thereof
CN118178476A (en) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） Application of Akkermansia and its preparation in the preparation of medicines for promoting defecation, fat excretion and reducing intestinal fat absorption
CN118207140B (en) * 2024-05-20 2024-09-17 微康益生菌(苏州)股份有限公司 Akkermansia muciniphila Akk11 with blood sugar and blood lipid regulating effect and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2103226A1 (en) * 2008-03-18 2009-09-23 Friesland Brands B.V. Long-life probiotic food product
NZ602704A (en) 2010-03-01 2015-01-30 Agronomique Inst Nat Rech Method of diagnostic of inflammatory bowel diseases
WO2013130773A2 (en) * 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders

Also Published As

Publication number Publication date
KR20150093711A (en) 2015-08-18
US20210393704A1 (en) 2021-12-23
US20200237832A1 (en) 2020-07-30
US20190282630A1 (en) 2019-09-19
KR20230121938A (en) 2023-08-21
ES2871817T3 (en) 2021-11-02
DK2919796T3 (en) 2021-05-31
PL3967315T3 (en) 2025-10-20
AU2013346726A1 (en) 2015-06-04
US20200121737A1 (en) 2020-04-23
JP6426616B2 (en) 2018-11-21
US20250288622A1 (en) 2025-09-18
CN104918626B (en) 2020-07-07
US20250288621A1 (en) 2025-09-18
KR20240137696A (en) 2024-09-20
KR102581171B1 (en) 2023-09-21
CN111603488B (en) 2024-04-05
KR20230080492A (en) 2023-06-07
KR102297388B9 (en) 2025-04-01
US20150306152A1 (en) 2015-10-29
AU2013346726B2 (en) 2017-11-02
MX365835B (en) 2019-06-17
BR112015011403A2 (en) 2018-02-06
KR20250048486A (en) 2025-04-08
PT2919796T (en) 2021-06-02
JP2016503418A (en) 2016-02-04
EA202100040A2 (en) 2021-06-30
WO2014076246A1 (en) 2014-05-22
KR20250049431A (en) 2025-04-11
JP2019048825A (en) 2019-03-28
HK1215375A1 (en) 2016-08-26
CN111603488A (en) 2020-09-01
EA201500535A1 (en) 2016-03-31
CA2891758A1 (en) 2014-05-22
EA202100040A3 (en) 2021-10-29
EA037315B1 (en) 2021-03-11
US20200237833A1 (en) 2020-07-30
MX2015006234A (en) 2015-10-29
CN104918626A (en) 2015-09-16
US20200155616A1 (en) 2020-05-21
KR102297388B1 (en) 2021-09-03
US20210322489A1 (en) 2021-10-21
ES3038019T3 (en) 2025-10-08
KR20210111871A (en) 2021-09-13
CA2891758C (en) 2022-06-07
ES3037446T3 (en) 2025-10-02
WO2014075745A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
PT2878018T (en) SUMMARY
PT2819623T (en) SUMMARY
EP2763896A4 (en) POLYROTOR TELEGUIDE
DK2859055T3 (en) POLYMERCOATINGS
DK2825087T3 (en) Otoscanner
DK2839013T3 (en) NON-DISRUPTIVE-GEN-TARGETING
EP2809145A4 (en) CHLOROPLASTTRANSITPEPTID
EP2805877A4 (en) SUB-RIBBON
DK2873977T3 (en) DOUBLE-RØRDISPENSER
DE112012006109A5 (en) Okklusionsschienenanordnung
DK2854722T3 (en) STOMIPOSE
PT2674413T (en) SUMMARY
PT2831109T (en) SUMMARY
PT2825212T (en) SUMMARY
DK2880228T3 (en) SCAFFOLDING STRUCTURE
EP2880400A4 (en) Kippa HAND
DK2825157T3 (en) AMINOSYRELIPIDER
EP2809729A4 (en) SILOXANPOLYETHERCOPOLYMER
DE112012006214T8 (en) Wulstringwickler
DK2831122T3 (en) Anthocyanidin-complex
DK2923109T3 (en) FLYWHEEL
PL2900676T3 (en) IMPROVED WAY TO ACYLATE MAJTANSINOL
BR302013000072S1 (en) CONFIGURATION APPLIED TO STACKER
DE112012005566T8 (en) Seltenerdnanoverbundmagnet
DK2885638T3 (en) MOLECULENET